GENIBET - BIOPHARMACEUTICALS SA

Their core work

GENIBET is a Portuguese biopharmaceutical SME specializing in vaccine development and biomanufacturing. They contribute GMP (Good Manufacturing Practice) production capabilities to European vaccine research consortia, bridging the gap between laboratory-scale vaccine candidates and clinical-grade production. Their work spans downstream processing of vaccines, preclinical development pipelines, and support for pan-European vaccine R&D infrastructure.

What they specialise in

How they've shifted over time

GENIBET's early H2020 work (2015–2017) centered on general vaccine production technology and process optimization, including nanobiotechnology-based downstream processing (DiViNe) and contributing to broad European vaccinology infrastructure (TRANSVAC2). From 2019 onward, their focus sharpened dramatically toward a specific therapeutic target — a Chagas disease vaccine requiring GMP production, toxicology studies, and Phase 1 clinical trial readiness — signaling a move from platform-level services toward disease-specific product development. This shift from infrastructure contributor to active drug development partner represents a significant maturation of the company's ambitions.

GENIBET is evolving from a vaccine manufacturing service provider toward a clinical development partner capable of taking vaccine candidates from bench to Phase 1 trials.

How they like to work

GENIBET always participates as a partner, never as coordinator, which is typical for a specialized SME contributing specific manufacturing or development capabilities to larger consortia. With 47 unique partners across 13 countries from just 4 projects, they operate in large, multi-national consortia — suggesting they are valued as a specialist contributor brought in for their biomanufacturing expertise. Their repeat involvement in the TRANSVAC network (both TRANSVAC2 and TRANSVAC-DS) indicates trusted relationships within the European vaccine infrastructure community.

Despite being a small company, GENIBET has built a wide network of 47 consortium partners across 13 countries through just 4 projects, reflecting the large-scale nature of European vaccine development consortia. Their geographic reach spans well beyond Portugal into the broader European vaccine research ecosystem.

What sets them apart

GENIBET occupies a rare niche as a Portuguese biopharmaceutical SME with GMP vaccine production capabilities integrated into Europe's core vaccine R&D infrastructure. Their combination of manufacturing know-how and active participation in disease-specific clinical development (Chagas) makes them more than a contract manufacturer — they are a development partner. For consortium builders, they offer the rare ability to handle the translation from research-grade vaccine candidates to clinical-grade material within a single organization.

Highlights from their portfolio

• CRUZIVAX
  Their largest project by far (EUR 861K of EUR 1.2M total funding), tackling a neglected tropical disease with a full pipeline from preclinical validation through GMP production to Phase 1 clinical trial.
• TRANSVAC2
  Part of the flagship European Vaccine Research and Development Infrastructure, positioning GENIBET within the continent's core vaccinology network.
• DiViNe
  Focused on improving vaccine downstream processing using nanobiotechnologies — directly tied to GENIBET's core manufacturing capabilities.